urea and cp 547632

urea has been researched along with cp 547632 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Atherton, J; Beebe, JS; Emerson, E; Finkelstein, M; Floyd, E; Foster, B; Gant, T; Goodwin, P; Harriman, S; Higdon, C; Hillerman, S; Jani, JP; Knauth, E; Kou, K; Marx, MA; Noe, MC; Rastinejad, F; Roberts, WG; Rossi, AM; Schaeffer, T; Soderstrom, C; Whalen, PM	1
Cohen, RB; Cosgriff, TM; Eisenberg, PD; Hainsworth, JD; Healey, D; Langer, CJ; Liau, K; Madajewicz, S; Pierce, K; Simon, GR; Xu, H	1

Trials

1 trial(s) available for urea and cp 547632

Article	Year
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea	2007

Article

Year

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1

Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea

2007

Other Studies

1 other study(ies) available for urea and cp 547632

Article	Year
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer research, 2003, Nov-01, Volume: 63, Issue:21 Topics: Animals; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Kinetics; Male; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; NIH 3T3 Cells; Phosphorylation; Rats; Rats, Sprague-Dawley; Thiazoles; Urea; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2003

Article

Year

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Cancer research, 2003, Nov-01, Volume: 63, Issue:21

Topics: Animals; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Kinetics; Male; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; NIH 3T3 Cells; Phosphorylation; Rats; Rats, Sprague-Dawley; Thiazoles; Urea; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2003